JAK2 and essential thrombocythemia: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) defined by sustained thrombocytosis, JAK2 V617F mutation in most cases, and elevated risks of thrombosis, bleeding, and secondary malignancies [3].